Yoshitomi Pharmaceutical Industries, Ltd.

Shigemi Kino

Hiroaki Mizuta

Tomonori Osajima

Kenji Ogawa

Kiyoshi Asano

Takako Shiotsuki

Minoru Oda

Hiroshi Yasumatsu

A method for the prophylaxis and treatment of irritable bowel syndrome, which comprises administering a pharmaceutically effective amount of at least one compound selected from the group consisting of (.+-.)-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino [5,4-c]pyridazin-3(2H)-one 7-oxide, optical isomers thereof and 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7,7-dioxide to a subject in need of such prophylaxis or treatment.

Method for prophylaxis and treatment of irritable bowel syndrome

A sustained release microsphere preparation which is produced by including a hydrophobic antipsychotic drug such as bromperidol, haloperidol or the like into a base composed of a high molecular weight polymer having in vivo histocompatibility such as polylactic acid, poly(lactic-co-glycolic)acid or the like, and a process for the production thereof.

Sustained release microsphere preparation containing antipsychotic drug

Pharmaceutical composition with improved dissolution property

Growing community of inventors

Fukuoka, Japan

Shigemi Kino